title: Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1).
abstract: Factor Xa, a serine protease, is at the critical juncture between the intrinsic and extrinsic pathways of the coagulation cascade. Inhibition of factor Xa has the potential to provide effective treatment for both venous and arterial thrombosis. We recently described a series of meta-substituted phenylpyrazoles that are highly potent, selective, and orally bioavailable factor Xa inhibitors. In this paper we report our efforts to further optimize the selectivity profile of our factor Xa inhibitors with a series of ortho- and/or para-substituted phenylpyrazole derivatives. The most potent compounds display sub-nanomolar inhibition constants for factor Xa and show greater than 1000-fold selectivity against other serine proteases. These compounds are also effective in a rabbit model of arteriovenous shunt thrombosis. Optimization of this series led to the preclinical development of DPC602, a 2-(aminomethyl)phenylpyrazole analogue, as a highly potent, selective, and orally bioavailable factor Xa inhibitor.
authors.affiliation: Bristol-Myers Squibb Company, Pharmaceutical Research Institute, 31 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, USA.
authors.forename: James R
authors.initials: JR
authors.lastname: Pruitt
authors.forename: Donald J P
authors.initials: DJ
authors.lastname: Pinto
authors.forename: Robert A
authors.initials: RA
authors.lastname: Galemmo
authors.forename: Richard S
authors.initials: RS
authors.lastname: Alexander
authors.forename: Karen A
authors.initials: KA
authors.lastname: Rossi
authors.forename: Brian L
authors.initials: BL
authors.lastname: Wells
authors.forename: Spencer
authors.initials: S
authors.lastname: Drummond
authors.forename: Lori L
authors.initials: LL
authors.lastname: Bostrom
authors.forename: Debra
authors.initials: D
authors.lastname: Burdick
authors.forename: Robert
authors.initials: R
authors.lastname: Bruckner
authors.forename: Haiying
authors.initials: H
authors.lastname: Chen
authors.forename: Angela
authors.initials: A
authors.lastname: Smallwood
authors.forename: Pancras C
authors.initials: PC
authors.lastname: Wong
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Wright
authors.forename: Steven
authors.initials: S
authors.lastname: Bai
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Luettgen
authors.forename: Robert M
authors.initials: RM
authors.lastname: Knabb
authors.forename: Patrick Y S
authors.initials: PY
authors.lastname: Lam
authors.forename: Ruth R
authors.initials: RR
authors.lastname: Wexler
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001166:Arteriovenous Shunt, Surgical; D001682:Biological Availability; D018360:Crystallography, X-Ray; D004285:Dogs; D015951:Factor Xa / Q000737:chemistry; D065427:Factor Xa Inhibitors; D006801:Humans; D011720:Pyrazoles / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D011817:Rabbits; D013329:Structure-Activity Relationship; D013927:Thrombosis / Q000517:prevention & control
chemical_list: C472001:DPC 602; D065427:Factor Xa Inhibitors; D011720:Pyrazoles; D015951:Factor Xa